<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Tax &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/tax/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 11 Oct 2026 08:22:52 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Tax &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Epigenetic Drug Valemetostat Shows Dual Action Against HTLV-1 Eye Inflammation</title>
		<link>https://bioengineer.org/epigenetic-drug-valemetostat-shows-dual-action-against-htlv-1-eye-inflammation/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sun, 11 Oct 2026 08:22:52 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[epigenetics]]></category>
		<category><![CDATA[EZH1]]></category>
		<category><![CDATA[EZH2]]></category>
		<category><![CDATA[H3K27me3]]></category>
		<category><![CDATA[HTLV-1]]></category>
		<category><![CDATA[IL-10]]></category>
		<category><![CDATA[NF-kappaB]]></category>
		<category><![CDATA[PRC2]]></category>
		<category><![CDATA[retinal pigment epithelium]]></category>
		<category><![CDATA[Tax]]></category>
		<category><![CDATA[uveitis]]></category>
		<category><![CDATA[valemetostat]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=414234</guid>

					<description><![CDATA[A new study shows that the dual EZH1/2 inhibitor valemetostat counteracts HTLV-1-induced epigenetic changes in retinal cells and suppresses viral transcription and inflammatory signaling in a model-dependent manner.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">414234</post-id>	</item>
	</channel>
</rss>
